ORIC-114 Phase 1 data shows first confirmed CNS complete response in EGFR exon 20 NSCLC

Oric Pharmaceuticals, Inc.

81% of EGFR exon 20 NSCLC patients had prior exon 20 targeted agents; 86% had CNS metastases at baseline.
At 75 mg QD (potential RP2D): 67% unconfirmed ORR and 33% confirmed ORR in post-amivantamab patients (n=3).
First confirmed CNS complete response reported by an EGFR exon 20 inhibitor in untreated brain metastases.
HER2 exon 20 patients: partial responses observed, including 100% target lesion regression.
Favorable safety: mostly Grade 1-2 TRAEs; no Grade 3+ rash; 4% discontinuations; MTD not reached.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.